Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.

Nobuhiro YamakawaMasahiro UmedaYumi YoshiiKenji MitsudoMakoto NoguchiJingo KusukawaAkira KatakuraHideki NakayamaMasashi SasakiTadahide NoguchiMichihiro UedaHiroki BukawaKazuhiro YagiharaAkihisa HorieAkihiro MiyazakiDaichi ChikazuKei TomiharaKatsuaki MishimaMitsunobu OtsuruSeiji AsodaShigeyoshi FujiwaraYoshio OhyamaHiroshi KuritaHitoshi KawamataMasayuki FukudaYukari ShintaniTakanori KobayashiTakahiro KannoIchiro Oh-IwaKenji KawanoYoshio YamashitaWataru KobayashiYoichi OhiroKatsuhiro UzawaYoshihide OtaTadaaki Kirita

Published in: Oral diseases (2022)

Nivolumab was effective for recurrent/metastatic oral squamous cell carcinoma treatment and was well tolerated by patients.

Keyphrases

end stage renal disease
squamous cell carcinoma
small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes
replacement therapy
smoking cessation